Trials / Withdrawn
WithdrawnNCT02246075
Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- FORUM Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of 2 fixed doses of EVP-6124 hydrochloride (HCl) compared to placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease who are concurrently receiving stable treatment with memantine and currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVP-6124 |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2016-10-01
- First posted
- 2014-09-22
- Last updated
- 2015-10-15
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02246075. Inclusion in this directory is not an endorsement.